Our Publications

As a science-driven company, we proudly publish numerous scientific papers every year in high-impact journals. Please feel free to contact our Science-team if you have questions or comments to our publications, or proposals for new scientific collaborations: science@nbcd.com

21 publications found

February 25, 2022
Osteoarthritis (OA) development programmes face challenges due to discordance between structural changes and symptoms. A novel cathepsin-K inhibitor, MIV-711, recently reported structural benefits, but did not demonstrate a significant difference from placebo in symptoms. Previous work suggests that pain from non-target joints may confound OA pain outcomes. We therefore conducted an exploratory analysis in participants with predominantly unilateral knee pain from the MIV-711-201 trial.

Osteoarthritis
June 22, 2021
To investigate acute changes in biochemical markers of bone and cartilage turnover in response to moderate intensity exercise with and without joint impact in healthy human subjects.

Osteoarthritis
Biomarkers
May 07, 2021
The FORWARD (FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses) trial assessed efficacy and safety of the potential disease-modifying osteoarthritis drug (DMOAD) sprifermin in patients with knee osteoarthritis. Here, we report 5-year efficacy and safety results.

Osteoarthritis
March 22, 2021
The heterogeneous nature of osteoarthritis (OA) and the need to subtype patients is widely accepted in the field. The biomarker CRPM, a metabolite of C-reactive protein (CRP), is released to the circulation during inflammation. Blood CRPM levels have shown to be associated with disease activity and response to treatment in rheumatoid arthritis (RA). We investigated the level of blood CRPM in OA compared to RA using data from two phase III knee OA and two RA studies (N = 1591).

Journals:
Scientific Reports
Osteoarthritis
Biomarkers
Rheumatoid Arthritis
March 03, 2021
To investigate acute changes in biochemical markers of cartilage turnover in response to moderate intensity exercise with and without joint impact in humans with knee osteoarthritis.

Osteoarthritis
Biomarkers
March 20, 2020
Clinical trials of new disease-modifying treatments for osteoarthritis should demonstrate a positive effect on a functional outcome or reduction in joint failure in order to be considered successful. Total joint replacement (TJR) surgery may be considered as joint failure, but great variation in the incidence of TJR complicates its use as a study endpoint. Factors predicting elevated risk of TJR could potentially be used to enrich such outcome-trials.

Osteoarthritis
March 20, 2020
We aimed to investigate existing literature on the impact of physical activity and exercise (PA) on joint biochemical markers (BM) and magnetic resonance imaging (MRI) outcomes in osteoarthritis (OA), and on this basis propose directions for future research. Literature Review. Original papers were identified in PubMed, Embase, and Scopus and data on study populations, activity, biomarkers, imaging, and outcomes were extracted and reviewed. 24 papers, mainly on knee OA, were included. PA indicated acute increase in cartilage turnover in OA patients, as indicated by changes in markers of extra cellular matrix (ECM) turnover.

Osteoarthritis
March 10, 2020
To propose a standardized model for exercise-induced cartilage turnover and investigate residual levels and dynamics of biomarker serum ARGS (sARGS) in primary osteoarthritis (OA) patients and a supportive group of young healthy subjects.

Osteoarthritis
Biomarkers
October 08, 2019
FORWARD (FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses) was a 5-year, dose-finding, multicenter randomized clinical trial conducted at 10 sites. Eligible participants were aged 40 to 85 years with symptomatic, radiographic knee osteoarthritis and Kellgren-Lawrence grade 2 or 3. Enrollment began in July 2013 and ended in May 2014; the last participant visit occurred on May 8, 2017. The primary outcome at 2 years and a follow-up analysis at 3 years are reported.

Journals:
JAMA
Osteoarthritis
September 03, 2019
Excessive cartilage degradation is a known characteristic of osteoarthritis (OA). Biochemical markers, such as uCTX-II, have been shown to be associated with disease severity, yet the tissue origin of CTX-II has been disputed. This analysis investigates the association between OA knee joints at different radiographic stages and pain categories with levels of uCTX-II and biomarkers of bone resorption and formation.

Osteoarthritis
Biomarkers